• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

GenEdit

Monday, June 03, 2024
CP
Multiple Therapeutics
GenEdit is developing genetic medicines with targeted in vivo delivery based on the NanoGalaxy® platform of non-viral, non-lipid hydrophilic nanoparticles (HNPs). HNPs offer a combination of advantages, including tissue selectivity, payload flexibility (siRNA, mRNA, gene editors up to 10 kB), low immunogenicity, ability to re-dose and ease of manufacturing. GenEdit identified HNPs that deliver to multiple tissues and cells such as antigen presenting cells in the spleen, neurons and glial cells in the brain or endothelium of the lung. GenEdit aims to leverage the full potential of the versatile HNP platform through the development of internal program to treat neurological diseases -currently in discovery stage- and partnerships in immunology, neurology and other therapeutic areas. GenEdit announced a multiyear collaboration and license agreement with Genentech to develop novel nanoparticles to deliver genetic medicines for autoimmune disease (January, 2023).
GenEdit
Company Website: https://genedit.com/
Lead Product in Development: Neuro disease area (target and indication not yet publicly disclosed)
Number Of Unlicensed Products (For Which You Are Seeking Partners): Seeking partnerships that are platform based. Many indications in neuro and immune (activation and tolerance), immune oncology are available.

Company HQ City

South San Francisco

Company HQ State

CA

Company HQ Country

United States

CEO/Top Company Official

Kunwoo Lee

Development Phase of Primary Product

Discovery
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS